Agree Goldman. Shareprice performance has been abysmal despite albeit slow progress on getting to Phase 3 status this year.
Talk of big pharma deal does not seem credible. I f big pharma were that excited by PAR why not just do a complete takeover on PAR given its micro capitalisation?
Something needs to give- either do a deal or be taken over. I do think the longer time goes on without a deal, the higher the risk becomes, not the other way around.
PAR Investor Meeting - Questions from HC, page-39
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.035(13.7%) |
Mkt cap ! $101.4M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 29.0¢ | 25.0¢ | $162.3K | 595.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 49897 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 24504 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |